Taiwan’s active pharmaceutical ingredient (API) industry showed brisk performance in recent years. Export grew five times over the past five years, with sales higher than those from pharmaceutical formulations. Since the domestic API market is limited in size, development of international markets has become an important strategy for Taiwan’s drug companies. To gain access to international niche markets, process technologies have been strengthened, and plants and laboratories for raw material production have been expanded. For example, in the third quarter of 2010, Everlight Chemical Industrial Corporation (永光化學) implemented a 5-year development plan with....